Should a third booster dose be scheduled after two doses of CoronaVac? A single‐center experience

In the 10th month of the pandemic, coronavirus disease 2019 (COVID‐19) vaccination was given first to healthcare workers in Turkey after receiving emergency use approval from the Ministry of Health. This study, which was performed at the COVID‐19 reference center in Ankara (the capital of Turkey) ai...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of medical virology Vol. 94; no. 1; pp. 287 - 290
Main Authors:	Yigit, Metin, Ozkaya‐Parlakay, Aslinur, Cosgun, Yasemin, Ince, Yunus E., Bulut, Yunus E., Senel, Emrah
Format:	Journal Article
Language:	English
Published:	United States Wiley Subscription Services, Inc 01-01-2022 John Wiley and Sons Inc
Subjects:	Adult Aged Antibodies, Neutralizing - blood Antibodies, Viral - blood booster dose Coronavirus Nucleocapsid Proteins - immunology Coronaviruses COVID-19 COVID-19 - immunology COVID-19 - prevention & control COVID-19 vaccines COVID-19 Vaccines - immunology Dosage Female Health care Health Personnel - statistics & numerical data Humans IgG antibody Immunization Immunization Schedule Immunization, Secondary - methods Immunoglobulin G Immunoglobulin G - blood Immunoglobulins inactivated vaccine Male Medical personnel Middle Aged Older people Pandemics Phosphoproteins - immunology Retrospective Studies SARS-CoV-2 - immunology Seroconversion Seroconversion - physiology Severe acute respiratory syndrome Severe acute respiratory syndrome coronavirus 2 Turkey Vaccination Vaccines Vaccines, Inactivated - immunology Vaccines, Synthetic - immunology Viral diseases Virology Young Adult Turkey COVID-19 booster dose inactivated vaccine
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	In the 10th month of the pandemic, coronavirus disease 2019 (COVID‐19) vaccination was given first to healthcare workers in Turkey after receiving emergency use approval from the Ministry of Health. This study, which was performed at the COVID‐19 reference center in Ankara (the capital of Turkey) aimed to evaluate the seroconversion rate of the CoronaVac vaccine. The anti‐spike immunoglobulin G response to the two‐dose vaccination was retrospectively examined in healthcare workers who had no previous history of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection. The postvaccine seroconversion rate was investigated by measuring the antibody levels of healthcare workers who had received CoronaVac. Vaccination was administered as 600 SU in 28‐day intervals. The healthcare workers' anti‐SARS‐CoV‐2 immunoglobulin G levels were used to determine the seroconversion rate 2 months after the second dose of the vaccine. Of the healthcare workers, 22.9% (n = 155) were seronegative. The younger the age of the participant, the higher the level of anti‐SARS‐CoV‐2 immunoglobulin G. Furthermore, anti‐SARS‐CoV‐2 immunoglobulin G levels were much higher in women than men. Highlights This study provided strong evidence for the administration of a booster dose.To the best of the authors' knowledge, this is the first study in the literature on the decrease of anti‐SARS‐CoV‐2 immunoglobulin G levels in older people.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	0146-6615 1096-9071 1096-9071
DOI:	10.1002/jmv.27318